Please assess the completion status of the following clinical trial:

Trial Title: YELLOW II Study: Reduction in Coronary Yellow Plaque, Lipids and Vascular Inflammation by Aggressive Lipid Lowering

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients \>18 years of age and willing to participate.~* Fluency in either English or Spanish.~* Stable patients who will undergo cardiac catheterization and PCI (intent to stent).~* Patient is willing to go on high-dose cholesterol lowering medication for the duration of the study~* Signed written Informed Consent.~* Women of childbearing potential must agree to be on an acceptable method of birth control/contraceptive such as barrier method (condoms/diaphragm); hormonal contraceptives (birth control pills, implants (Norplant) or injections (Depo-Provera)); Intrauterine Device.~* Proposed non-culprit YELLOW study lesion with max 4mm LCBI ≥ 150.~Exclusion Criteria:~* Patients who have acute myocardial infarction (ST-segment elevation presentation, new Q waves or non-ST segment elevation with CK-MB \> 5 times above the upper normal (31.5 ng/ml) within 72 hours).~* Patients who are in cardiogenic shock.~* Patients requiring coronary artery bypass graft surgery.~* Patients with platelet count \< 100,000 cell/mm3.~* Patients who have co-morbidity which reduces life expectancy to one year.~* Patients who are currently participating in another investigational drug/device study.~* Patients with liver disease.~* Patient with creatinine \> 2.0 mg/dL.~* Pregnant women and women of childbearing potential who intend to have children during the duration of the trial.~* Patients having undergone heart transplantation, or those that may undergo heart transplantation during the study period.~* Active autoimmune disease.~* Nursing mothers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- rosuvastatin (Type: EXPERIMENTAL): All subjects will receive rosuvastatin 40mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).